Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) said on Thursday that it has entered into an exclusive agreement with influenza vaccine company CSL Seqirus for the marketing and distribution of its three proprietary vaccines in Germany.

The partnership will begin with CSL Seqirus commercialising Valneva's chikungunya vaccine IXCHIQ in July 2025, followed by IXIARO for Japanese encephalitis and DUKORAL for cholera and ETEC in January 2026.

This agreement replaces Valneva's current distribution arrangement with Bavarian Nordic, which concludes at the end of December 2025.

The new three-year agreement includes minimum annual purchasing volumes and standard termination provisions.

Valneva stated that CSL Seqirus' strong commercial presence will support continued growth in Germany, Europe's largest travel vaccine market.

In the first quarter of 2025 Valneva reported EUR48.6m in product sales, with EUR42.8m generated from its proprietary vaccines. The company expects full-year product sales to reach EUR170-180m, contributing to positive cash flow from its commercial operations.